Periodic Reporting for period 1 - OrganoidsFHeartbreak (Organoids For Heartbreak)
Berichtszeitraum: 2023-09-01 bis 2025-08-31
Zusammenfassung vom Kontext und den Gesamtzielen des Projekts
Context and Overall Objectives of the Project
Cardiovascular disease remains the leading cause of mortality in Europe, with post-injury cardiac remodelling and fibrosis representing major contributors to long-term morbidity and death. Current preclinical models, predominantly 2D monocultures or small-animal systems fail to capture the cellular diversity, mechanical environment, and complex signaling interactions of the human heart. As a result, approximately 90% of drug candidates fail in early clinical testing, underscoring an urgent need for physiologically relevant human in vitro models of cardiac fibrosis that can reliably predict therapeutic responses.
The OrganoidsFHeartbreak project was conceived to address these unmet needs by developing an advanced human induced pluripotent stem cell (hiPSC)–based, three-cell-type spheroid model capable of reproducing the molecular and functional hallmarks of cardiac fibrosis. The scientific rationale rests on the critical role of fibroblast activation—driven by TGF-β and other pro-fibrotic cues, extracellular matrix accumulation, tissue stiffening, and progressive loss of cardiac function. A robust and inducible fibrosis model is therefore essential for understanding pathological mechanisms and for enabling early-stage drug discovery.
The overall objective of the project was to establish a reproducible, physiologically relevant 3D cardiac organoid platform integrating hiPSC-derived cardiomyocytes, endothelial cells, and fibroblasts, and to validate its suitability for automated, high-content analysis of fibrosis initiation and inhibition.
Specific goals included:
1. Generating and optimising the derivation of all three cardiac cell types, including development of a new differentiation strategy to obtain quiescent, stimulus-responsive hiPSC-derived fibroblasts.
2. Assembling multicellular cardiac spheroids with defined size and cell ratios, and demonstrating their structural integrity and lineage composition.
3. Inducing fibrosis with canonical activators (TGF-β1, Ang II) and quantifying fibrotic marker expression at both protein and transcript levels.
4. Integrating high-throughput kinetic image cytometry with customised CellProfiler pipelines to establish an automated, unbiased fibrosis-detection system.
5. Assessing functional consequences of fibrosis on contractility and calcium handling to confirm that the organoids reproduce clinically relevant aspects of cardiac dysfunction.
Project Pathway to Impact
The project positioned itself at the intersection of regenerative medicine, drug discovery, and advanced in vitro modelling. By overcoming major technical limitations—most critically, the generation of quiescent and activatable fibroblasts—the work produced a validated human 3D fibrosis model ready for further optimisation toward large-scale screening applications. The integration of automated imaging with quantitative image-analysis pipelines demonstrates that fibrotic activation and inhibition can be reliably detected across spheroids, establishing a methodological framework directly transferable to pharmaceutical screening workflows.
The project’s pathway to impact is therefore threefold:
Scientific impact:
Provides a high-fidelity human model to study early mechanisms of cardiac fibrosis.
Offers a platform for testing targeted therapies that modulate fibroblast activation and extracellular-matrix dynamics.
Enables multi-marker, multiparametric readouts compatible with modern high-content screening technologies.
Technological impact:
Delivers an automated, reproducible workflow combining organoid culture, kinetic imaging, and computational analysis.
Establishes protocols adaptable to 96- and 384-well formats, a prerequisite for high-throughput drug discovery pipelines.
Demonstrates functional readouts (contractility, calcium flux) that complement structural fibrosis markers.
Translational and societal impact:
Enhances early-stage identification of promising anti-fibrotic compounds, accelerating development pipelines.
Reduces reliance on animal models by providing a reliable human-based alternative.
Contributes to EU priorities in precision medicine and improved cardiovascular health outcomes.
In summary, the OrganoidsFHeartbreak project successfully lays the scientific and technological foundation for a next-generation human cardiac fibrosis platform. It addresses clear biomedical and translational needs and establishes a credible pathway toward impactful future applications in drug discovery, personalised medicine, and mechanistic research.
Cardiovascular disease remains the leading cause of mortality in Europe, with post-injury cardiac remodelling and fibrosis representing major contributors to long-term morbidity and death. Current preclinical models, predominantly 2D monocultures or small-animal systems fail to capture the cellular diversity, mechanical environment, and complex signaling interactions of the human heart. As a result, approximately 90% of drug candidates fail in early clinical testing, underscoring an urgent need for physiologically relevant human in vitro models of cardiac fibrosis that can reliably predict therapeutic responses.
The OrganoidsFHeartbreak project was conceived to address these unmet needs by developing an advanced human induced pluripotent stem cell (hiPSC)–based, three-cell-type spheroid model capable of reproducing the molecular and functional hallmarks of cardiac fibrosis. The scientific rationale rests on the critical role of fibroblast activation—driven by TGF-β and other pro-fibrotic cues, extracellular matrix accumulation, tissue stiffening, and progressive loss of cardiac function. A robust and inducible fibrosis model is therefore essential for understanding pathological mechanisms and for enabling early-stage drug discovery.
The overall objective of the project was to establish a reproducible, physiologically relevant 3D cardiac organoid platform integrating hiPSC-derived cardiomyocytes, endothelial cells, and fibroblasts, and to validate its suitability for automated, high-content analysis of fibrosis initiation and inhibition.
Specific goals included:
1. Generating and optimising the derivation of all three cardiac cell types, including development of a new differentiation strategy to obtain quiescent, stimulus-responsive hiPSC-derived fibroblasts.
2. Assembling multicellular cardiac spheroids with defined size and cell ratios, and demonstrating their structural integrity and lineage composition.
3. Inducing fibrosis with canonical activators (TGF-β1, Ang II) and quantifying fibrotic marker expression at both protein and transcript levels.
4. Integrating high-throughput kinetic image cytometry with customised CellProfiler pipelines to establish an automated, unbiased fibrosis-detection system.
5. Assessing functional consequences of fibrosis on contractility and calcium handling to confirm that the organoids reproduce clinically relevant aspects of cardiac dysfunction.
Project Pathway to Impact
The project positioned itself at the intersection of regenerative medicine, drug discovery, and advanced in vitro modelling. By overcoming major technical limitations—most critically, the generation of quiescent and activatable fibroblasts—the work produced a validated human 3D fibrosis model ready for further optimisation toward large-scale screening applications. The integration of automated imaging with quantitative image-analysis pipelines demonstrates that fibrotic activation and inhibition can be reliably detected across spheroids, establishing a methodological framework directly transferable to pharmaceutical screening workflows.
The project’s pathway to impact is therefore threefold:
Scientific impact:
Provides a high-fidelity human model to study early mechanisms of cardiac fibrosis.
Offers a platform for testing targeted therapies that modulate fibroblast activation and extracellular-matrix dynamics.
Enables multi-marker, multiparametric readouts compatible with modern high-content screening technologies.
Technological impact:
Delivers an automated, reproducible workflow combining organoid culture, kinetic imaging, and computational analysis.
Establishes protocols adaptable to 96- and 384-well formats, a prerequisite for high-throughput drug discovery pipelines.
Demonstrates functional readouts (contractility, calcium flux) that complement structural fibrosis markers.
Translational and societal impact:
Enhances early-stage identification of promising anti-fibrotic compounds, accelerating development pipelines.
Reduces reliance on animal models by providing a reliable human-based alternative.
Contributes to EU priorities in precision medicine and improved cardiovascular health outcomes.
In summary, the OrganoidsFHeartbreak project successfully lays the scientific and technological foundation for a next-generation human cardiac fibrosis platform. It addresses clear biomedical and translational needs and establishes a credible pathway toward impactful future applications in drug discovery, personalised medicine, and mechanistic research.
Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse
Activities Performed and Main Scientific Achievements
1. Establishment and Optimisation of hiPSC-Derived Cardiac Cell Types
A major part of the project focused on generating the three essential cardiac cell populations—cardiomyocytes (hiPSC-CMs), endothelial cells (hiPSC-ECs), and cardiac fibroblasts (hiPSC-FBs)—needed for a physiologically relevant fibrosis model.
hiPSC-ECs:
Two differentiation protocols were systematically compared, revealing instability in endothelial phenotype using the initially planned method. A refined protocol integrating VEGF165, Forskolin, and DAPT produced stable, reproducible hiPSC-ECs with confirmed expression of CDH5 and PECAM1.
hiPSC-CMs:
hiPSC-CMs were successfully generated using an in-house Wnt-modulation strategy. Differentiation efficiency consistently exceeded 95% TNNT2⁺ cells, confirmed by immunofluorescence and flow cytometry.
hiPSC-FBs:
This task represented the main scientific challenge. Facility-derived hiPSC-FBs were found to be constitutively activated and non-responsive to pro-fibrotic stimulation. Intensive troubleshooting was required, including attempts to revert fibrosis via cultivation on soft substrates and TGF-β inhibition - both unsuccessful.
Ultimately, a new differentiation protocol incorporating late-stage TGF-β inhibition was established, generating quiescent, activatable fibroblasts that significantly increased ACTA2, COL1A1/COL3A1, FN1, and POSTN upon stimulation. The response was confirmed on transcriptional and protein level. This outcome was a key breakthrough enabling all subsequent work.
2. Fibrosis Induction and Marker Validation in Monolayer Systems
The newly generated hiPSC-FBs were systematically stimulated with TGF-β1, Ang II, or both. Quantitative RT-qPCR and immunofluorescence confirmed robust upregulation of fibrotic markers at both transcript and protein levels.
An extensive antibody screening panel (11 candidates) was performed to identify reliable markers for high-throughput imaging. FN1 and ACTA2 emerged as the most reproducible readouts, forming the basis of downstream automated analysis pipelines.
3. Development of High-Throughput Imaging and Image Analysis Pipelines
A major technical achievement was the integration of Kinetic Image Cytometry (KIC) with customised CellProfiler pipelines:
Automated, whole-well scanning provided 25 images per well, ensuring comprehensive quantification.
A novel pipeline for extracellular matrix (ECM) detection was designed, enabling image-level quantification of FN1 and COL1 normalized per nucleus.
The system demonstrated sensitivity to both fibrosis activation and inhibition, validating its suitability for high-content screening.
This combined hardware–software framework forms the technological core of the project’s impact pathway.
4. Assembly and Validation of Three-Cell Cardiac Spheroids
Because alginate-drop generators were unavailable, spheroid assembly was redesigned to a centrifugation-based U-bottom method, which supported:
i. Consistent spheroid size (~50,000 cells)
ii. Optimal handling for immunofluorescence
iii. Compatibility with high-throughput plates
All three cell types successfully integrated into compact, viable spheroids. Immunostaining confirmed cardiomyocyte (TNNT2), endothelial (PECAM1), and fibroblast (ACTA2/DDR2) presence within each organoid.
5. Fibrosis Modelling in 3D Cardiac Organoids
Fibrosis was induced with TGF-β1 and inhibited with SB431542. FN1 emerged as the most reliable ECM marker in 3D culture.
High-throughput KIC imaging showed:
i. Strong upregulation of FN1 upon TGF-β stimulation.
ii. Suppression of signal following ALK5 inhibition (SB431542).
iii. Significant differences in both FN1 intensity and spheroid area.
These findings validated the 3D model as responsive to pro- and anti-fibrotic cues.
Due to microscopy penetration limits, ACTA2 expression could not be conclusively mapped throughout whole spheroids, despite successful clearing. Microtome slicing was attempted but tissue fragility and poor antigen preservation prevented consistent sectioning.
6. Functional Assessment of Fibrotic Spheroids
To evaluate whether fibrosis translated into functional impairment:
i. Contractility was assessed using brightfield videos analysed by MUSCLEMOTION.
ii. TGF-β spheroids showed an increased spontaneous beat rate and a trend toward reduced contraction amplitude, although changes did not reach significance.
iii. Calcium handling was analysed using Cal520-based calcium imaging.
iv. No major differences in transient amplitude or kinetics were detected across conditions.
v. Under electrical pacing, TGF-β spheroids demonstrated double stimulation at 1 Hz, indicating subtle alterations in electrophysiological responsiveness.
These results suggest that structural fibrosis signatures do not necessarily translate into major calcium-handling defects in this organoid model—but contractile behaviour shows early signs of dysregulation.
Main Achievements and Final Outcomes
1. A fully reproducible three-cell-type human cardiac organoid platform was established, integrating cardiomyocytes, endothelial cells, and fibroblasts.
2. A new differentiation method for quiescent, activatable hiPSC-derived fibroblasts was successfully implemented, resolving a key bottleneck and enabling accurate fibrosis induction.
3. The project produced a validated fibrosis model responsive to both TGF-β activation and SB431542 inhibition, recapitulating essential hallmarks of human cardiac fibrosis.
4. An automated high-throughput imaging and quantification pipeline was created, enabling unbiased detection of ECM deposition and intracellular marker expression at scale.
5. Functional analyses (contractility and calcium flux) were integrated to complement structural fibrosis markers, resulting in a holistic, multiparametric model.
6. The platform provides a strong technological basis for future drug-screening applications, even though large-scale compound testing could not be completed within the project timeframe.
Collectively, the project delivered a robust, high-content-compatible human cardiac fibrosis organoid model, fulfilling its core scientific objectives and establishing a foundation for future translational and pharmacological applications.
1. Establishment and Optimisation of hiPSC-Derived Cardiac Cell Types
A major part of the project focused on generating the three essential cardiac cell populations—cardiomyocytes (hiPSC-CMs), endothelial cells (hiPSC-ECs), and cardiac fibroblasts (hiPSC-FBs)—needed for a physiologically relevant fibrosis model.
hiPSC-ECs:
Two differentiation protocols were systematically compared, revealing instability in endothelial phenotype using the initially planned method. A refined protocol integrating VEGF165, Forskolin, and DAPT produced stable, reproducible hiPSC-ECs with confirmed expression of CDH5 and PECAM1.
hiPSC-CMs:
hiPSC-CMs were successfully generated using an in-house Wnt-modulation strategy. Differentiation efficiency consistently exceeded 95% TNNT2⁺ cells, confirmed by immunofluorescence and flow cytometry.
hiPSC-FBs:
This task represented the main scientific challenge. Facility-derived hiPSC-FBs were found to be constitutively activated and non-responsive to pro-fibrotic stimulation. Intensive troubleshooting was required, including attempts to revert fibrosis via cultivation on soft substrates and TGF-β inhibition - both unsuccessful.
Ultimately, a new differentiation protocol incorporating late-stage TGF-β inhibition was established, generating quiescent, activatable fibroblasts that significantly increased ACTA2, COL1A1/COL3A1, FN1, and POSTN upon stimulation. The response was confirmed on transcriptional and protein level. This outcome was a key breakthrough enabling all subsequent work.
2. Fibrosis Induction and Marker Validation in Monolayer Systems
The newly generated hiPSC-FBs were systematically stimulated with TGF-β1, Ang II, or both. Quantitative RT-qPCR and immunofluorescence confirmed robust upregulation of fibrotic markers at both transcript and protein levels.
An extensive antibody screening panel (11 candidates) was performed to identify reliable markers for high-throughput imaging. FN1 and ACTA2 emerged as the most reproducible readouts, forming the basis of downstream automated analysis pipelines.
3. Development of High-Throughput Imaging and Image Analysis Pipelines
A major technical achievement was the integration of Kinetic Image Cytometry (KIC) with customised CellProfiler pipelines:
Automated, whole-well scanning provided 25 images per well, ensuring comprehensive quantification.
A novel pipeline for extracellular matrix (ECM) detection was designed, enabling image-level quantification of FN1 and COL1 normalized per nucleus.
The system demonstrated sensitivity to both fibrosis activation and inhibition, validating its suitability for high-content screening.
This combined hardware–software framework forms the technological core of the project’s impact pathway.
4. Assembly and Validation of Three-Cell Cardiac Spheroids
Because alginate-drop generators were unavailable, spheroid assembly was redesigned to a centrifugation-based U-bottom method, which supported:
i. Consistent spheroid size (~50,000 cells)
ii. Optimal handling for immunofluorescence
iii. Compatibility with high-throughput plates
All three cell types successfully integrated into compact, viable spheroids. Immunostaining confirmed cardiomyocyte (TNNT2), endothelial (PECAM1), and fibroblast (ACTA2/DDR2) presence within each organoid.
5. Fibrosis Modelling in 3D Cardiac Organoids
Fibrosis was induced with TGF-β1 and inhibited with SB431542. FN1 emerged as the most reliable ECM marker in 3D culture.
High-throughput KIC imaging showed:
i. Strong upregulation of FN1 upon TGF-β stimulation.
ii. Suppression of signal following ALK5 inhibition (SB431542).
iii. Significant differences in both FN1 intensity and spheroid area.
These findings validated the 3D model as responsive to pro- and anti-fibrotic cues.
Due to microscopy penetration limits, ACTA2 expression could not be conclusively mapped throughout whole spheroids, despite successful clearing. Microtome slicing was attempted but tissue fragility and poor antigen preservation prevented consistent sectioning.
6. Functional Assessment of Fibrotic Spheroids
To evaluate whether fibrosis translated into functional impairment:
i. Contractility was assessed using brightfield videos analysed by MUSCLEMOTION.
ii. TGF-β spheroids showed an increased spontaneous beat rate and a trend toward reduced contraction amplitude, although changes did not reach significance.
iii. Calcium handling was analysed using Cal520-based calcium imaging.
iv. No major differences in transient amplitude or kinetics were detected across conditions.
v. Under electrical pacing, TGF-β spheroids demonstrated double stimulation at 1 Hz, indicating subtle alterations in electrophysiological responsiveness.
These results suggest that structural fibrosis signatures do not necessarily translate into major calcium-handling defects in this organoid model—but contractile behaviour shows early signs of dysregulation.
Main Achievements and Final Outcomes
1. A fully reproducible three-cell-type human cardiac organoid platform was established, integrating cardiomyocytes, endothelial cells, and fibroblasts.
2. A new differentiation method for quiescent, activatable hiPSC-derived fibroblasts was successfully implemented, resolving a key bottleneck and enabling accurate fibrosis induction.
3. The project produced a validated fibrosis model responsive to both TGF-β activation and SB431542 inhibition, recapitulating essential hallmarks of human cardiac fibrosis.
4. An automated high-throughput imaging and quantification pipeline was created, enabling unbiased detection of ECM deposition and intracellular marker expression at scale.
5. Functional analyses (contractility and calcium flux) were integrated to complement structural fibrosis markers, resulting in a holistic, multiparametric model.
6. The platform provides a strong technological basis for future drug-screening applications, even though large-scale compound testing could not be completed within the project timeframe.
Collectively, the project delivered a robust, high-content-compatible human cardiac fibrosis organoid model, fulfilling its core scientific objectives and establishing a foundation for future translational and pharmacological applications.
Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)
Results and Potential Impacts, and Key Needs for Further Uptake and Success
1. Overview of Results
The OrganoidsFHeartbreak project successfully developed a technically robust, physiologically relevant 3D human cardiac fibrosis model integrating hiPSC-derived cardiomyocytes, endothelial cells, and quiescent fibroblasts.
The major scientific outcomes of the project include:
1. Establishment of quiescent, activatable hiPSC-FBs, representing a key methodological advance and enabling reliable fibrosis induction at both transcript and protein levels.
2. Creation of reproducible three-cell-type cardiac spheroids with validated lineage composition and structural integrity.
3. Successful induction and inhibition of fibrosis in 3D organoids using TGF-β activation and SB431542 inhibition, respectively, with FN1 emerging as a robust ECM readout.
4. Development of an automated, scalable high-content imaging pipeline, combining kinetic image cytometry with a customised CellProfiler workflow optimised for both intracellular and extracellular fibrosis markers.
5. Functional assessment of organoids, demonstrating subtle but detectable TGF-β–associated changes in contractility and electrophysiological responsiveness.
Together, these outputs provide a validated mid-throughput preclinical platform with direct applicability for mechanistic studies and early-stage compound screening.
2. Scientific and Technological Impact
The project delivers several impactful innovations:
i. A new gold-standard method for generating quiescent, activatable cardiac fibroblasts from hiPSCs, directly addressing a long-standing bottleneck in the field.
ii. A multi-lineage cardiac spheroid model that more accurately reflects human fibrotic remodeling than conventional monolayer or single-cell-type systems.
iii. A fully automated imaging and analysis workflow that is easily scalable to 96- or 384-well plate formats and compatible with industrial high-throughput screening infrastructure.
iv. A validated fibrosis readout based on FN1 accumulation and ACTA2 induction, enabling quantitative assessment of both pro- and anti-fibrotic signals.
These technological achievements significantly strengthen European capabilities in human-relevant cardiac disease modelling and support EU objectives in reducing reliance on animal testing and accelerating translational medicine.
3. Potential Applications and Longer-Term Impact
The platform developed in this project provides a strong foundation for:
i. High-content drug screening for anti-fibrotic compounds.
ii. Mechanistic studies aimed at dissecting fibroblast activation, ECM remodeling, and cardiomyocyte–fibroblast–endothelial interactions.
iii. Preclinical testing of biologics, gene therapies, or small molecules targeting TGF-β signaling, integrins, collagen cross-linking, or matrix turnover pathways.
iv. Personalisation of fibrosis modelling, using patient-specific iPSCs to study genotype-driven differences in disease progression.
v. Regenerative medicine strategies, including testing of pro-repair and anti-scarring interventions.
By enabling more predictive, humanised fibrosis assays, the project contributes to lowering drug-development attrition rates and improving safety and efficacy assessments prior to clinical trials.
4. Key Needs to Ensure Further Uptake and Success
To translate the platform into a mature drug-screening and commercial tool, several key enablers are required:
4.1 Further Scientific and Technical Development
i. SOP development for ensuring cross-laboratory reproducibility.
ii. High-penetrance imaging (e.g. light-sheet microscopy) to overcome limitations in ACTA2 detection in thick organoid tissue.
iii. Incorporation of additional physiological readouts, such as tissue stiffness, collagen cross-linking, or long-term electrical stimulation.
4.2 Validation and Demonstration
i. Benchmarking using clinically approved anti-fibrotic compounds, to establish assay predictiveness.
ii. Ring-testing across laboratories to validate robustness and user transferability.
iii. Dose–response modelling, essential for pre-commercial assay validation.
4.3 Access to Infrastructure and Markets
i. High-throughput robotic systems for automated organoid handling and compound dispensing.
ii. Industrial partnerships with pharmaceutical and biotech companies to integrate the assay into discovery pipelines.
iii. Pathway-to-market analysis, focusing on assay licensing, platform integration, and potential for contract research applications.
4.4 Intellectual Property and Commercialisation
i. Assessment of freedom-to-operate (FTO) in hiPSC-derived cardiac disease modelling.
ii. Development of a commercial kit or ready-to-use assay enabling companies to run the fibrosis platform in-house.
4.5 Regulatory and Standardisation Framework
i. Alignment with OECD guidelines for in vitro testing.
ii. Contribution to emerging ISO standards for organoid-based assays.
iii. Early dialogue with regulatory agencies (EMA, FDA) regarding qualification of advanced in vitro fibrosis models for drug screening.
5. Expected Long-Term Impact
Once fully developed and validated, the cardiac fibrosis organoid platform is expected to:
i. Improve early-stage identification of anti-fibrotic drugs, reducing late-stage clinical failures.
ii. Reduce the use of animal models in preclinical fibrosis research.
iii. Strengthen Europe’s leadership in organoid technology, phenotypic screening, and human-relevant toxicology.
iv. Accelerate therapeutic development for patients suffering from myocardial injury and chronic cardiac fibrosis.
Ultimately, the project delivers a scientifically rigorous and technologically advanced foundation with clear potential to impact translational research, precision cardiology, and pharmaceutical innovation.
1. Overview of Results
The OrganoidsFHeartbreak project successfully developed a technically robust, physiologically relevant 3D human cardiac fibrosis model integrating hiPSC-derived cardiomyocytes, endothelial cells, and quiescent fibroblasts.
The major scientific outcomes of the project include:
1. Establishment of quiescent, activatable hiPSC-FBs, representing a key methodological advance and enabling reliable fibrosis induction at both transcript and protein levels.
2. Creation of reproducible three-cell-type cardiac spheroids with validated lineage composition and structural integrity.
3. Successful induction and inhibition of fibrosis in 3D organoids using TGF-β activation and SB431542 inhibition, respectively, with FN1 emerging as a robust ECM readout.
4. Development of an automated, scalable high-content imaging pipeline, combining kinetic image cytometry with a customised CellProfiler workflow optimised for both intracellular and extracellular fibrosis markers.
5. Functional assessment of organoids, demonstrating subtle but detectable TGF-β–associated changes in contractility and electrophysiological responsiveness.
Together, these outputs provide a validated mid-throughput preclinical platform with direct applicability for mechanistic studies and early-stage compound screening.
2. Scientific and Technological Impact
The project delivers several impactful innovations:
i. A new gold-standard method for generating quiescent, activatable cardiac fibroblasts from hiPSCs, directly addressing a long-standing bottleneck in the field.
ii. A multi-lineage cardiac spheroid model that more accurately reflects human fibrotic remodeling than conventional monolayer or single-cell-type systems.
iii. A fully automated imaging and analysis workflow that is easily scalable to 96- or 384-well plate formats and compatible with industrial high-throughput screening infrastructure.
iv. A validated fibrosis readout based on FN1 accumulation and ACTA2 induction, enabling quantitative assessment of both pro- and anti-fibrotic signals.
These technological achievements significantly strengthen European capabilities in human-relevant cardiac disease modelling and support EU objectives in reducing reliance on animal testing and accelerating translational medicine.
3. Potential Applications and Longer-Term Impact
The platform developed in this project provides a strong foundation for:
i. High-content drug screening for anti-fibrotic compounds.
ii. Mechanistic studies aimed at dissecting fibroblast activation, ECM remodeling, and cardiomyocyte–fibroblast–endothelial interactions.
iii. Preclinical testing of biologics, gene therapies, or small molecules targeting TGF-β signaling, integrins, collagen cross-linking, or matrix turnover pathways.
iv. Personalisation of fibrosis modelling, using patient-specific iPSCs to study genotype-driven differences in disease progression.
v. Regenerative medicine strategies, including testing of pro-repair and anti-scarring interventions.
By enabling more predictive, humanised fibrosis assays, the project contributes to lowering drug-development attrition rates and improving safety and efficacy assessments prior to clinical trials.
4. Key Needs to Ensure Further Uptake and Success
To translate the platform into a mature drug-screening and commercial tool, several key enablers are required:
4.1 Further Scientific and Technical Development
i. SOP development for ensuring cross-laboratory reproducibility.
ii. High-penetrance imaging (e.g. light-sheet microscopy) to overcome limitations in ACTA2 detection in thick organoid tissue.
iii. Incorporation of additional physiological readouts, such as tissue stiffness, collagen cross-linking, or long-term electrical stimulation.
4.2 Validation and Demonstration
i. Benchmarking using clinically approved anti-fibrotic compounds, to establish assay predictiveness.
ii. Ring-testing across laboratories to validate robustness and user transferability.
iii. Dose–response modelling, essential for pre-commercial assay validation.
4.3 Access to Infrastructure and Markets
i. High-throughput robotic systems for automated organoid handling and compound dispensing.
ii. Industrial partnerships with pharmaceutical and biotech companies to integrate the assay into discovery pipelines.
iii. Pathway-to-market analysis, focusing on assay licensing, platform integration, and potential for contract research applications.
4.4 Intellectual Property and Commercialisation
i. Assessment of freedom-to-operate (FTO) in hiPSC-derived cardiac disease modelling.
ii. Development of a commercial kit or ready-to-use assay enabling companies to run the fibrosis platform in-house.
4.5 Regulatory and Standardisation Framework
i. Alignment with OECD guidelines for in vitro testing.
ii. Contribution to emerging ISO standards for organoid-based assays.
iii. Early dialogue with regulatory agencies (EMA, FDA) regarding qualification of advanced in vitro fibrosis models for drug screening.
5. Expected Long-Term Impact
Once fully developed and validated, the cardiac fibrosis organoid platform is expected to:
i. Improve early-stage identification of anti-fibrotic drugs, reducing late-stage clinical failures.
ii. Reduce the use of animal models in preclinical fibrosis research.
iii. Strengthen Europe’s leadership in organoid technology, phenotypic screening, and human-relevant toxicology.
iv. Accelerate therapeutic development for patients suffering from myocardial injury and chronic cardiac fibrosis.
Ultimately, the project delivers a scientifically rigorous and technologically advanced foundation with clear potential to impact translational research, precision cardiology, and pharmaceutical innovation.